Evgen Pharma has announced a new collaboration with the Universita Sapienza di Roma to investigate the potential radiosensitisation effects of Evgen’s lead cancer drug SFX-01. SFX-01 is the anti-cancer drug sulforaphane stabilised using Evgen’s Suforadex technology platform. SFX-01 has already completed a phase II open label study in the treatment of metastatic breast cancer and is being evaluated in the brain cancer glioblastoma, which is due to commence a Phase II study in H2 2022 (where in th ....
